I raised a suggestion to you 10-days ago about
inquiring with the oncologist regarding use of either Zoledronic acid (Zometa) or Denosumab (Xgeva) for the purposes of PREVENTING skeletal-related events (SREs). SREs are distressingly common amongst men with bone mets, and have a deleterious effect on patients.
The two drugs I've listed are NOT cancer-fighting; rather, they slow and delay the continuous & accelerated
bone decay that is taking place now which is putting dad at greater risk of a serious & sudden SRE set-back which—while not typically fatal itself—can lead to such a rapid decline in health and well-being that mortality often follows quickly. (Quite frankly and honestly, when an advanced cancer patient too weakened to take additional chemotherapy suddenly gets placed permanently into a wheelchair—a common outcome—following a SRE with the associated loss of independence, etc., their will-to-live is often very quickly sapped.)
A SRE can happen to weakened bones from an otherwise seemingly minor fall, and even by bumping into something or having something dropped onto his lap. If untreated (with one of the drugs I listed), half of all advanced prostate cancer patients with bone metastases will experience
at least one SRE over the first 2-year period since M1b diagnosis, and once a patient experiences an SRE, the risk of a subsequent SRE is increased.
In addition, though you have mentioned dad has not yet reported bone pain, these drugs also palliate the very typical and common bone pain which eventually accompanies virtually all M1b…but for now, preventing SREs is critical.
I stressed that these two bone-targeted therapies are NOT cancer-fighting drugs, and note that they are NOT as aggressive on the body as chemotherapies…but there ARE
possible side effects including kidney function impairment which can be managed to some degree by adjusting dosage at each administration (several weeks apart). Dad may be too weak for chemo, but may NOT be too weak for one of these preventative drugs; if when asked, the doctors say that he is too weak for either of these bone drugs, then that says a lot.
I thought I’d raise this again because I’ve seen no mention of it in your posts over the last 10-days, despite visiting several oncologists. If he’s too weak, then he’s too weak…but it is, I believe as I said on 4/19, of great importance to maintaining quality of life for dad and therefore worthy of inquiry.
Learn a bit more about
SREs and their prevention here:
Post Edited (NKinney) : 4/30/2018 9:15:07 AM (GMT-6)